Domzalski David 4

What Happened

• David Domzalski, President, CEO and Director of VYNE Therapeutics (VYNE), had 12,214 shares withheld by the company to satisfy tax withholding related to the vesting of restricted stock units (RSUs). The shares were valued at $0.65 each, totaling $7,948. This is a tax-withholding disposition (not an open-market sale).

Key Details

• Transaction date: 2026-06-30; filing date: 2026-07-02 (filed within the required Form 4 window).
• Price: $0.65 per share; total value of shares withheld: $7,948.
• Transaction code: F — shares were withheld to satisfy tax withholding on RSU vesting.
• Footnote: F1 — "Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."
• Shares owned after the transaction: not provided in the information supplied.

Context

• This was a routine net-share settlement to cover tax liabilities on vested RSUs, not a market sale; such withholdings are common and generally do not indicate a change in the insider’s view of the company.
• For retail investors: purchases or open-market buys tend to be more meaningful as bullish signals; tax withholdings are administrative and should be interpreted accordingly.